Trifarotene 50 µg/G Cream for Treatment of Acne Vulgaris – A Summary of Two Randomized Trials and a Long-Term Safety Study

Main Article Content

Jerry Tan
James Del Rosso
Jonathan Weiss
Linda Stein Gold
Fran Cook-Bolden
Lawrence Eichenfeld
Emil Tanghetti
Alessandra Alió Saenz
Faiz Ahmad

Keywords

Acne Vulgaris, Acne, trifarotene, retinoid, Safety

Abstract

Abstract not available.

References

1. Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, et al. Randomized phase 3 evaluation of trifarotene 50 mg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80:1691-9.

2. Blume-Peytavi U, Fowler J, Lajos K, Draelos Z, Cook-Bolden F, Dirschka T, et al. Long-term safety and efficacy of trifarotene 50μg/g cream, a first-inclass RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2019:(In preparation).